1. Home
  2. Labeler Index
  3. Northwind Pharmaceuticals, Llc
  4. 51655-967
  5. Product Images: Alfuzosin Hydrochloride

Product Images Alfuzosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 51655-967 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

51655-967-52 - 51655 967 52 Rev A 06 23

51655-967-52 - 51655 967 52 Rev A 06 23

NDC: 51655-967-52 is the National Drug Code for Alfuzosin Hydrochloride Extended-Release Tablets, USP. Each tablet contains 10mg of Alfuzosin hydrochloride. This medication is available in a pack of 30 tablets and requires a prescription. It should be stored between 20°C - 25°C (68°F - 77°F), protected from light and moisture, and kept out of the reach of children. The repackaging has been done by Northwind Pharmaceuticals in Indianapolis, IN. The lot number provided is 0000000000, and the expiration date is 00/00/0000.*

Molecular Structure - ef35abcf e0b6 4551 84cf a689ad11e6cd 01

Molecular Structure - ef35abcf e0b6 4551 84cf a689ad11e6cd 01

Figure 1 - ef35abcf e0b6 4551 84cf a689ad11e6cd 02

Figure 1 - ef35abcf e0b6 4551 84cf a689ad11e6cd 02

Figure 2 - ef35abcf e0b6 4551 84cf a689ad11e6cd 03

Figure 2 - ef35abcf e0b6 4551 84cf a689ad11e6cd 03

This text provides information regarding the mean change in a study comparing a placebo group (N=167) to a group taking altuzosin hydrochloride extended-release tablets (N=170). The study measured the mean change over a treatment period of 28, 56, and 84 days. The significance level (p-value) for the observed differences is indicated to be less than 0.001, suggesting a statistically significant effect of the treatment.*

Figure 3 - ef35abcf e0b6 4551 84cf a689ad11e6cd 04

Figure 3 - ef35abcf e0b6 4551 84cf a689ad11e6cd 04

The text provided indicates a comparison of mean change between a placebo group (consisting of 152 individuals) and a group administered with alfuzosin hydrochloride extended-release tablets (consisting of 137 individuals) over a treatment period of 28, 56, and 84 days. The significance level of the test is indicated by **p < 0.01.*

Figure 4 - ef35abcf e0b6 4551 84cf a689ad11e6cd 05

Figure 4 - ef35abcf e0b6 4551 84cf a689ad11e6cd 05

Figure 5 - ef35abcf e0b6 4551 84cf a689ad11e6cd 06

Figure 5 - ef35abcf e0b6 4551 84cf a689ad11e6cd 06

Figure 6 - ef35abcf e0b6 4551 84cf a689ad11e6cd 07

Figure 6 - ef35abcf e0b6 4551 84cf a689ad11e6cd 07

Figure 7 - ef35abcf e0b6 4551 84cf a689ad11e6cd 08

Figure 7 - ef35abcf e0b6 4551 84cf a689ad11e6cd 08

This text appears to be a table displaying the mean change in mL/s over different days of treatment for a Placebo group and a group receiving Altuzosin hydrochloride extended-release tablets. The table includes data for 14, 28, 56, and 84 days of treatment. The statistical significance (p-value) is also mentioned.*

Company Logo - ef35abcf e0b6 4551 84cf a689ad11e6cd 09

Company Logo - ef35abcf e0b6 4551 84cf a689ad11e6cd 09

Not available*

Company Logo - ef35abcf e0b6 4551 84cf a689ad11e6cd 10

Company Logo - ef35abcf e0b6 4551 84cf a689ad11e6cd 10

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.